Potential population health outcomes and expenditures of HIV vaccination strategies in the United States
about
HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysisCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersThe Potential Cost-Effectiveness of HIV Vaccines: A Systematic ReviewConceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--2.Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United StatesExpanded HIV testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the United KingdomThe cost-effectiveness of a modestly effective HIV vaccine in the United States.The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial resultsThe cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections.Mathematical models for the study of HIV spread and control amongst men who have sex with men.The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2.
P2860
Q28478017-AE14249A-EE9D-4B00-A18A-DFDBA1188DE0Q28483820-C0D54893-AFA3-434B-BA58-A3E80F579969Q28973596-21070307-6CBD-4085-9265-83D903EEC0F3Q30595581-232FE56A-225E-4BCD-A77A-F0B4B80197DEQ33696533-BE66F7BB-2CEE-468D-8E26-0C4EEF9EF46CQ33855920-AB7F6F8C-B7D5-4DDE-AC8F-F60E85202954Q35157015-08D1917C-2F95-4BA2-B15A-6BCD9F6C4B83Q35165189-D375967F-EEFC-402E-9541-064D2423B06BQ35187930-821ED2A7-A920-4E47-A589-25CB062A7CE2Q35214966-9F8FE707-3E6F-494C-9DE8-E32107C3A76DQ36950527-A88B2DCA-B79A-431B-8EDC-1EBEF4096EA2Q37203626-F0085ECE-CEF7-4901-96AC-05A4199F91E7Q37499070-6FD2EDD5-131A-46F1-B552-1323D87D8E51Q37935620-51B14DFA-9CF0-49E1-B773-EEFFE3B9521AQ52567034-4837F52E-B84D-40AA-B143-0A89C2C96890Q53123531-939761B5-BE2F-46A4-83F5-2255DD0C3BF7
P2860
Potential population health outcomes and expenditures of HIV vaccination strategies in the United States
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential population health ou ...... trategies in the United States
@en
Potential population health ou ...... rategies in the United States.
@nl
type
label
Potential population health ou ...... trategies in the United States
@en
Potential population health ou ...... rategies in the United States.
@nl
prefLabel
Potential population health ou ...... trategies in the United States
@en
Potential population health ou ...... rategies in the United States.
@nl
P2093
P2860
P1433
P1476
Potential population health ou ...... trategies in the United States
@en
P2093
Douglas K Owens
Elisa F Long
Margaret L Brandeau
P2860
P304
P356
10.1016/J.VACCINE.2009.06.063
P407
P577
2009-07-08T00:00:00Z